FDA approves former Genmab drug - royalties to follow
The US health authority, the FDA, has approved Horizon Therapeutics' eye medicine teprotumumab, which may earn Genmab a significant amount in royalties.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.
Try us for 14 days
Try a trial subscription for access to our quality journalism